盐酸贝尼地平
Search documents
湖南方盛制药股份有限公司关于公司《药品生产许可证》变更的公告
Shang Hai Zheng Quan Bao· 2025-10-21 18:38
Core Points - The company has completed the change registration of its "Drug Production License" and obtained the new license from the Hunan Provincial Drug Administration [1] - The validity of the "Drug Production License" has been extended to October 16, 2030 [1][3] - The company has made several changes to its production lines and added new products to its production scope [1][3] License Change Details - The license validity has been extended from December 3, 2025, to October 16, 2030 [1] - The production address for the raw material drug (Ibandronate) has been updated to "Raw Material Drug Workshop (Workshop 101) B Area and E Area" [1] - The company has added the production of "Raw Material Drug (Benidipine Hydrochloride)" at the same production address [1] - The company has commissioned Tian Di Heng Yi Pharmaceutical Co., Ltd. to produce "Yuan Qi Bone Pain Tincture" with a validity until October 16, 2030 [1] - Additional commissioned production information has been included for two products: "Flurbiprofen Gel Patch" and "Compound Glycyrrhizin Tablets" [1] Production Scope and Impact - The production scope includes various forms of drugs such as powder injections, tablets, hard capsules, and raw materials [3] - The changes in the "Drug Production License" will not affect the company's existing production structure and will maintain stable production capacity [3] - The new license is not expected to have a significant impact on the company's current performance [3]
方盛制药:公司药品生产许可证变更
2 1 Shi Ji Jing Ji Bao Dao· 2025-10-21 10:06
Core Viewpoint - The company has received a renewed drug production license from the Hunan Provincial Drug Administration, which includes several changes to its production capabilities and license validity [1] Summary by Relevant Sections - **License Renewal**: The drug production license has been extended until October 16, 2030 [1] - **Production Changes**: Modifications include changes to the production line for the raw material drug Ezetimibe and the addition of the raw material drug Benidipine to the production scope [1] - **Operational Stability**: The changes will not affect the company's existing production structure, ensuring stable production capacity [1] - **License Number**: The new license number is 湘20150028 [1]